Expert Insights: Managing Patients with CKD, Hyperkalemia, and Continued RAASi Therapy Through a Case Study Approach

View this accredited e-learning program with a focus on heart failure at our partner website ReachMD, a leading online learning platform for physicians and other healthcare professionals

Hyperkalemia (HK) is a major impediment to optimizing RAASi therapy in various patient populations. Fortunately, newer treatments are now available to mitigate this adverse effect.

Follow this case presentation, featuring Drs. Matthew Weir, Gates Colbert, and Robert Toto to discover strategies for overcoming concerns about hyperkalemia in patients with CKD receiving RAAS inhibitor therapy.

Educational information

Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

• Matthew R. Weir, MD, Division Head, Nephrology, University of Maryland, School of Medicine, Baltimore, MD, USA
• Gates Colbert, MD, FASN, Assistant Clinical Professor, Texas A&M College of Medicine, Dallas, TX , USA
• Robert Toto, MD, Associate Dean, Translational Science, UT Southwestern Medical Center, Dallas, TX, USA

Disclosures

This activity is supported by an independent educational grant from Vifor Pharma.

View e-learning at ReachMD